Table 2.
Current clinical trials investigating the role of γδ T cells in AML
| Agent | Description | Ph. | Dose (cells/kg) | Population | Rec. | NCT |
| TCB-202-001 | Ex vivo expanded allogeneic Vγ9Vδ2 T cells | I | 1×106
1×107 1×108 |
R/R AML | C | NCT0379007265 |
| TCB-008 | Ex vivo expanded allogeneic γδ T cells | II | 7×107 or 7×108 | R/R AML, MRD+ | R | NCT0535880866 |
| INB-100 | Allogeneic γδ T cells | I | 1×106
3×106 |
R/R AML | R | NCT0353381670 |
| ICT01+VEN/AZA | Vγ9Vδ2 T cell activator (anti-BTN3A(CD 277)mAb) | II | – | Newly diagnosed AML | R | NCT0424349977 |
| γδ T cell infusion | Artificial APC-expanded donor γδ T cell infusion | I/Ib | 1×106
5×106 2.5×107 1×108 |
R/R AML | R | NCT0501542679 |
| GDX012 | Allogeneic γδ1 T cells | I | – | R/R AML | NYR | NCT0588649180 |
| LAVA-051* | CD1d-Vδ2TCR (Vγ9Vδ2 T cell) engager and iNKT activator (bispecific antibody) | I/IIa | 100 µg | R/R CLL, MM, AML | ANR | NCT0488725981 |
| CTM-N2D | iPSC-derived γδ2 T cells (NKG2D CAR) | I | 1×107
5×108 3×108 1×109 |
Multiple cancers | NYR | NCT0530203782 |
| ADI001 | Allogeneic Vδ1 γδ T cells (CD20 CAR) | I | – | R/R B-cell NHL, DLBCL | R | NCT0473547183 84 |
| ADI925 | Vδ1 T cells (chimeric adapter) | – | – | Multiple cancers | – | -85 |
*Development has been discontinued.
AML, acute myeloid leukemia; ANR, active but not recruiting; APC, antigen-presenting cell(s); C, completed recruitment; CAR, chimeric antigen receptor; DLBCL, diffuse large B cell lymphoma; iPSC, induced pluripotent stem cells; mAb, monoclonal antibody; MRD, measurable residual disease; NCT, National Clinical Trial identifier; NHL, non-Hodgkin's lymphoma; NYR, not yet recruiting; Ph, phase; R, recruiting; Rec, recruitment status; R/R, relapsed/refractory; VEN/AZA, venetoclax/azacytidine.